NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

Phase 3

Active, not recruiting

Conditions: Stage II Lung Non-Small Cell Cancer AJCC v7
Stage IB Lung Non-Small Cell Carcinoma AJCC v7
Stage IIIA Lung Non-Small Cell Cancer AJCC v7

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography Test
Biological: Nivolumab
Other: Observation Activity
Procedure: Positron Emission Tomography

First Posted Date: 2015-11-04

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 903

Registration Number: NCT02595944

Locations: 🇺🇸
Crossroads Cancer Center, Effingham, Illinois, United States
🇺🇸
Reid Health, Richmond, Indiana, United States
🇺🇸
Bronson Battle Creek, Battle Creek, Michigan, United States

and more 882 locations

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

Phase 1

Active, not recruiting

Conditions: Stage II Vaginal Cancer AJCC v6 and v7
Stage IVA Vaginal Cancer AJCC v6 and v7
Advanced Vaginal Adenocarcinoma
Advanced Vaginal Adenosquamous Carcinoma
Advanced Vaginal Squamous Cell Carcinoma
Stage IVA Cervical Cancer AJCC v6 and v7
Stage IIIB Cervical Cancer AJCC v6 and v7
Advanced Cervical Adenocarcinoma
Advanced Cervical Adenosquamous Carcinoma
Advanced Cervical Squamous Cell Carcinoma

Interventions: Procedure: Biospecimen Collection
Radiation: Brachytherapy
Drug: Cisplatin
Procedure: Computed Tomography
Radiation: External Beam Radiation Therapy
Other: Fludeoxyglucose F-18
Radiation: High-Dose Rate Brachytherapy
Radiation: Intensity-Modulated Radiation Therapy
Procedure: Magnetic Resonance Imaging
Other: Pharmacological Study
Procedure: Positron Emission Tomography
Drug: Triapine

First Posted Date: 2015-11-04

Last Posted Date: 2025-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT02595879

Locations: 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 14 locations

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2

Active, not recruiting

Conditions: Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Ovarian Serous Tumor
Recurrent Primary Peritoneal Carcinoma

Interventions: Drug: Berzosertib
Drug: Gemcitabine
Drug: Gemcitabine Hydrochloride

First Posted Date: 2015-11-04

Last Posted Date: 2025-02-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT02595892

Locations: 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States

and more 14 locations

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1

Active, not recruiting

Conditions: Metastatic Pancreatic Carcinoma
Refractory Pancreatic Carcinoma
Stage IV Pancreatic Cancer AJCC v8
Refractory Colorectal Carcinoma
Metastatic Lung Small Cell Carcinoma
Stage III Pancreatic Cancer AJCC v8
Stage IV Colorectal Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Unresectable Colorectal Carcinoma
Unresectable Lung Small Cell Carcinoma

Interventions: Drug: Berzosertib
Procedure: Biopsy Specimen
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Irinotecan Hydrochloride

First Posted Date: 2015-11-04

Last Posted Date: 2025-03-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 66

Registration Number: NCT02595931

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States

and more 20 locations

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Phase 1

Completed

Conditions: Hepatocellular Carcinoma
HIV Infection
Locally Advanced Malignant Solid Neoplasm
Metastatic Lung Non-Small Cell Carcinoma
Kaposi Sarcoma
Metastatic Melanoma
Clinical Stage III Cutaneous Melanoma AJCC v8
Clinical Stage IV Cutaneous Melanoma AJCC v8
Locally Advanced Lung Non-Small Cell Carcinoma
Metastatic Malignant Solid Neoplasm

Interventions: Drug: Antiretroviral Therapy
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Pembrolizumab
Procedure: Positron Emission Tomography

First Posted Date: 2015-11-04

Last Posted Date: 2024-08-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 58

Registration Number: NCT02595866

Locations: 🇺🇸
Louisiana State University Health Science Center, New Orleans, Louisiana, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
Mount Sinai Hospital, New York, New York, United States

and more 9 locations

Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue

Recruiting

Conditions: Prostate Cancer

First Posted Date: 2015-11-03

Last Posted Date: 2025-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3000

Registration Number: NCT02594202

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors

Phase 1

Active, not recruiting

Conditions: Metastatic Lung Non-Small Cell Carcinoma
Metastatic Lung Small Cell Carcinoma
Metastatic Lung Neuroendocrine Neoplasm
Stage IVB Lung Cancer AJCC v8
Metastatic Malignant Neoplasm in the Brain
Stage IVA Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8

Interventions: Drug: Berzosertib
Other: Quality-of-Life Assessment
Procedure: Therapeutic Conventional Surgery
Radiation: Whole-Brain Radiotherapy

First Posted Date: 2015-10-28

Last Posted Date: 2025-03-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT02589522

Locations: 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States

and more 6 locations

Evaluation of the Sensitivity of Endoscopy to Detect Nasopharyngeal Carcinoma (NPC) in an Epstein-Barr Virus (EBV)-Based NPC Screening Project in China

Completed

Conditions: Nasopharyngeal Cancinoma (NPC)

First Posted Date: 2015-10-26

Last Posted Date: 2020-12-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 828

Registration Number: NCT02586532

Locations: 🇨🇳
Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Phase 2

Active, not recruiting

Conditions: Metastatic Melanoma
Stage IV Cutaneous Melanoma AJCC v6 and v7
Recurrent Cutaneous Melanoma

Interventions: Drug: Ibrutinib
Other: Laboratory Biomarker Analysis
Other: Pharmacogenomic Study
Other: Pharmacological Study

First Posted Date: 2015-10-21

Last Posted Date: 2025-03-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT02581930

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States

and more 10 locations

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

Phase 2

Recruiting

Conditions: Common Variable Immunodeficiency
Primary T-cell Immunodeficiency Disorders
Immune System Diseases
Autoimmune Lymphoproliferative
Lymphoproliferative Disorders

Interventions: Drug: Reduced Intensity Conditioning
Drug: Myeloablative Conditioning-Closed with amendment L
Drug: Immunosuppression Only Conditioning -Closed with amendment L
Drug: GVHD Prophylaxis
Procedure: Allo BMT

First Posted Date: 2015-10-20

Last Posted Date: 2025-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 254

Registration Number: NCT02579967

Locations: 🇺🇸
National Marrow Donor Program, Minneapolis, Minnesota, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy